V Square Quantitative Management LLC Acquires 2,434 Shares of IQVIA Holdings Inc. (NYSE:IQV)

V Square Quantitative Management LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 146.8% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,092 shares of the medical research company’s stock after acquiring an additional 2,434 shares during the quarter. V Square Quantitative Management LLC’s holdings in IQVIA were worth $865,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. Lazard Asset Management LLC raised its stake in IQVIA by 0.9% during the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after buying an additional 30,014 shares during the last quarter. Canada Pension Plan Investment Board increased its holdings in IQVIA by 6.4% in the first quarter. Canada Pension Plan Investment Board now owns 3,191,835 shares of the medical research company’s stock worth $807,183,000 after purchasing an additional 193,304 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of IQVIA by 3.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock worth $634,927,000 after buying an additional 92,293 shares in the last quarter. Capital Research Global Investors lifted its position in shares of IQVIA by 7.2% during the 1st quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock valued at $540,882,000 after acquiring an additional 143,533 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in IQVIA by 339.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after acquiring an additional 1,597,003 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

IQV traded down $1.04 on Wednesday, hitting $237.40. 198,088 shares of the company’s stock traded hands, compared to its average volume of 1,079,231. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company’s 50 day simple moving average is $223.52 and its 200-day simple moving average is $231.62. The firm has a market cap of $43.28 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 2.24 and a beta of 1.49.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the previous year, the firm posted $2.22 EPS. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.23 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on IQV shares. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a report on Monday, August 5th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Jefferies Financial Group cut IQVIA from a “buy” rating to a “hold” rating and dropped their price target for the company from $266.00 to $242.00 in a research report on Wednesday, July 24th. Robert W. Baird upped their price objective on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a report on Tuesday, July 23rd. Finally, StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $265.67.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.